A retrospective study of crossover ambulatory oxygen walk testing in patients with fibrotic lung disease

• DOI: 10.1016/j.resinv.2023.04.002
• Publication Date: 2023-05-10T18:09:47Z
• Authors: Manjit K. Cartlidge; Hazel Wilkie; Feng Li; Jill Macleod; Lisa Nicol; Gareth Stewart; Roberto A. Rabino...; Karen Linton; Sarah McNamara; Alex Przybylski; Nik Hirani
• Keywords: Oxygen; Cross-Over Studies; Oxygen Inhalation Therapy; Humans; Lung Diseases, Interstitial; Lung; 3. Good health; Retrospective Studies

Fibrotic interstitial lung disease (ILD) comprises a group of lung conditions that are often progressive, debilitating, and life-shortening. Ambulatory oxygen therapy (AOT) is regularly prescribed to manage symptoms in patients with fibrotic ILD. In our institution, the decision to prescribe portable oxygen is made on the basis of oxygen improving exercise capacity, measured with the single-blinded, crossover ambulatory oxygen walk test (AOWT). This study aimed to investigate the characteristics and survival rates of patients with fibrotic ILD who have either positive or negative results on the AOWT.This retrospective cohort study compared the data from 99 patients with fibrotic ILD who underwent the AOWT. These patients were classified into two groups based on whether they showed improvement in the AOWT with supplemental oxygen (positive group) or no improvement (negative group). Patient demographics for both groups were compared to determine any significant differences. A multivariate Cox proportional hazards model was used to analyze the survival rates of the two groups.Out of the 99 patients, 71 were in the positive group. We compared the measured characteristics between the positive and negative groups and found no significant difference, wherein the adjusted hazard ratio was 1.33 (95% confidence interval 0.69-2.60, P = 0.40).The AOWT can be used to rationalize AOT, but there was no significant difference in baseline characteristics or survival rates between patients whose performance was improved or not in the AOWT.